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Adjunctive selective estrogen receptor modulator increases
neural activity in the hippocampus and inferior frontal
gyrus during emotional face recognition in schizophrenia
E Ji1,2, CS Weickert1,2,3, R Lenroot1,2,3, J Kindler1,2,4, AJ Skilleter1,2,3, A Vercammen1,2,3, C White5, RE Gur6 and TW Weickert1,2,3
Estrogen has been implicated in the development and course of schizophrenia with most evidence suggesting a neuroprotective
effect. Treatment with raloxifene, a selective estrogen receptor modulator, can reduce symptom severity, improve cognition and
normalize brain activity during learning in schizophrenia. People with schizophrenia are especially impaired in the identiﬁcation of
negative facial emotions. The present study was designed to determine the extent to which adjunctive raloxifene treatment would
alter abnormal neural activity during angry facial emotion recognition in schizophrenia. Twenty people with schizophrenia (12 men,
8 women) participated in a 13-week, randomized, double-blind, placebo-controlled, crossover trial of adjunctive raloxifene treatment
(120 mg per day orally) and performed a facial emotion recognition task during functional magnetic resonance imaging after each
treatment phase. Two-sample t-tests in regions of interest selected a priori were performed to assess activation differences between
raloxifene and placebo conditions during the recognition of angry faces. Adjunctive raloxifene signiﬁcantly increased activation in
the right hippocampus and left inferior frontal gyrus compared with the placebo condition (family-wise error, Po0.05). There was no
signiﬁcant difference in performance accuracy or reaction time between active and placebo conditions. To the best of our
knowledge, this study provides the ﬁrst evidence suggesting that adjunctive raloxifene treatment changes neural activity in brain
regions associated with facial emotion recognition in schizophrenia. These ﬁndings support the hypothesis that estrogen plays a
modifying role in schizophrenia and shows that adjunctive raloxifene treatment may reverse abnormal neural activity during facial
emotion recognition, which is relevant to impaired social functioning in men and women with schizophrenia.
Translational Psychiatry (2016) 6, e795; doi:10.1038/tp.2016.59; published online 3 May 2016
INTRODUCTION
Schizophrenia is a disabling psychiatric disorder, with a 70–80%
unemployment rate,1 associated with multifaceted deﬁcits in
cognitive function2,3 and emotion processing.4,5 Although anti-
psychotics are the ﬁrst line of treatment for schizophrenia, these
medications are often limited in their effectiveness and leave
many patients with residual symptoms while producing unwanted
side effects.6 There is growing evidence that sex hormones may
inﬂuence the course and symptoms of schizophrenia. The onset of
the disease typically occurs during adolescence7 and the clinical
presentation, response to treatment and symptom severity can
differ between men and women.8–10 Schizophrenia occurs less
frequently and has a later average age of onset in women.11,12
Furthermore, women tend to experience a less-severe course of
the disease compared with men.9 Studies have found lower
estrogen levels in women with schizophrenia relative to healthy
women, relapses are more frequent when estrogen levels are low,
such as during the early follicular phase of the menstrual cycle,
postpartum and after menopause when there is a second peak of
illness onset and a more severe course of illness.13–18 These
ﬁndings support the estrogen hypothesis of schizophrenia that
posits that estrogen may have a neuroprotective effect against the
disease.19
Alterations in dopaminergic and serotonergic systems are
also key components of schizophrenia pathogenesis and animal
research has shown a modulatory effect of estrogen upon
dopamine and serotonin neurotransmitter systems in the
brain.20–23 The neurobiological beneﬁt of estrogen24 has led to
an increase in the number of studies investigating estrogen as a
potential therapeutic treatment in schizophrenia.25–30 Despite
growing positive evidence that estrogen may reduce symptom
severity in schizophrenia and may beneﬁt cognition during
aging,31–33 little is known regarding the therapeutic effects of
estrogen on aspects of schizophrenia that are relatively unre-
sponsive to standard therapeutic intervention, such as cognitive
dysfunction and social impairment.
Selective estrogen receptor modulators (SERMs) speciﬁcally
activate estrogen receptors and no other nuclear receptors.34,35
Unlike estrogen, SERMs do not stimulate estrogen receptors in the
breast or uterine tissue (therefore, avoiding any adverse effects in
these tissues). Raloxifene is a ﬁrst-generation SERM that is used to
treat osteoporosis in postmenopausal women36 and has demon-
strated beneﬁts in preventing age-related decreases in neural
activity in healthy older men.37 More recently, adjunctive treatment
with raloxifene in postmenopausal women with schizophrenia has
demonstrated reductions in positive and negative symptom
1School of Psychiatry, University of New South Wales, Randwick, NSW, Australia; 2Neuroscience Research Australia, Randwick, NSW, Australia; 3Schizophrenia Research Institute,
Darlinghurst, NSW, Australia; 4University Hospital of Child and Adolescent Psychiatry, University of Bern, Bern, Switzerland; 5Department of Endocrinology, Prince of Wales
Hospital, Randwick, NSW, Australia and 6Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Correspondence: Dr TW
Weickert, School of Psychiatry, University of New South Wales and Neuroscience Research Australia, Barker Street, Randwick, NSW 2031, Australia.
E-mail: t.weickert@neura.edu.au
Received 16 December 2015; revised 29 February 2016; accepted 5 March 2016
Citation: Transl Psychiatry (2016) 6, e795; doi:10.1038/tp.2016.59
www.nature.com/tp
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
82
67
1 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
severity and general psychopathology.38,39 A recent clinical trial
has shown that adjunctive raloxifene administered at 60 mg
per day improved memory and verbal ﬂuency in postmenopausal
women with schizophrenia.40 In addition, we have shown that
daily, oral adjunctive raloxifene treatment at 120 mg per day
improved verbal memory and attention and increased the brain
activity during learning in both men and women with
schizophrenia.41,42 However, no clinical trial to date has examined
the extent to which adjunctive raloxifene treatment may inﬂuence
facial emotion recognition, which is a critical skill linked to social
function in men and women with schizophrenia.43
Poor social functioning is a core feature of schizophrenia44 that
is associated with deﬁcits in emotion processing in which people
with schizophrenia often have difﬁculty identifying and discrimi-
nating among different facial expressions.45 Most evidence
suggests that people with schizophrenia display hypoactivation
in frontal and limbic regions and perform worse relative to healthy
individuals during facial emotion identiﬁcation tasks.46–48 The
regions of particular interest in relation to facial emotion
recognition are the bilateral amygdala, hippocampus and inferior
frontal gyrus (IFG). Amygdala damage has been linked to impaired
recognition of fearful and angry facial expressions.49–51 Further,
amygdala dysfunction has been implicated in facial emotion
processing tasks in people with schizophrenia, with several
studies reporting both hyper- or hypoactivation.52–55 Thus,
although functional abnormality of the amygdala in schizophrenia
is well established, the exact direction of the disruption remains
unclear.
The neural activity in the hippocampus is associated with
amygdala activity and emotional memory. The hippocampus
represents a key interface between sensory systems and the
limbic system, and is necessary to form and elicit long-term
memories.56 It has been suggested that the hippocampus encodes
the emotional sense of experiences so that they may be recalled
at a later time in association with an emotional valence.57
Together, the hippocampus and amygdala interact during
emotion processing and emotional memory retrieval.58,59
Regarding the cortical IFG, a meta-analysis of 105 functional
magnetic resonance imaging (fMRI) studies in healthy participants
reported signiﬁcantly increased IFG activation during the proces-
sing of angry faces relative to a baseline control condition.60 In
schizophrenia, the fMRI studies report abnormal IFG activation
during semantic processing61 and emotion processing.62 We
recently reported lower levels of neural activity in the left IFG in
schizophrenia relative to healthy controls during recognition of
negative facial emotions.47
The aim of the present study was to determine the extent to
which a hormone intervention therapy using the SERM raloxifene
will inﬂuence neural activity underlying recognition of facial
emotions in men and women with schizophrenia. For the fMRI
analysis, we focused on cortical and subcortical regions of interest
where there is evidence of functional abnormalities during the
facial emotion recognition in people with schizophrenia compared
with healthy controls: the amygdala, hippocampus and IFG. We
focused on angry versus neutral faces because people with
schizophrenia are particularly impaired in the identiﬁcation of
faces displaying negative emotions.63,64 Further, there is evidence
of a relationship between the magnitude of brain activity during
processing of direct social threat (anger) and symptom improve-
ment in people with schizophrenia, whereas this relationship
was not found for indirect threat (fear).65 We predicted that
administration of raloxifene will increase brain activity in the
hippocampus and IFG in men and women with schizophrenia,
compared with the placebo. Owing to contrasting reports
regarding the direction of abnormal amygdala activation in
schizophrenia, we had a non-directional hypothesis that raloxifene
would have a signiﬁcant inﬂuence on neural activity relative to
placebo in the amygdala.
MATERIALS AND METHODS
Participants
The study sample consisted of 20 people with schizophrenia or
schizoaffective disorder (12 male, 8 female). Patients were recruited via a
national television documentary, the outpatient mental health unit at the
Prince of Wales Hospital and community mental health clinics in the South
Eastern Sydney and Illawarra Area Health Service. All the patients were
between 22 and 51 years of age and were receiving antipsychotic
medication for at least 1 year before taking part in the study. Clinical
diagnostic interviews using the Structured Clinical Interview for DSM-IV66
were performed by a trained psychologist or psychiatrist. The symptom
severity was assessed using the Positive and Negative Syndrome Scale
(PANSS).67 The duration of illness was deﬁned as the difference between
the age at ﬁrst hospitalization and age at the time of scanning. The
exclusion criteria included a comorbid Axis I DSM-IV disorder, substance
abuse or dependency within the past 5 years, seizures, central nervous
system infection, uncontrolled diabetes or hypertension, a history of
neurological illness, head injury with loss of consciousness, structural brain
abnormalities as assessed by MRI scan, intellectual disability (current
intelligence quotient o70) or contraindications to the administration of
raloxifene. Women were excluded if they were currently pregnant or were
receiving hormone therapy and refused alternate forms of birth control.
See Table 1 for demographic and clinical characteristics of the sample.
The fasting peripheral blood samples were collected between 0900 and
1100 h to control for alterations in hormone levels due to diurnal
variations. The clotted and heparinized blood were delivered on ice to the
Prince of Wales Hospital South Eastern Area Laboratory Services Pathology
Unit immediately following collection. Prolactin, follicle-stimulating hor-
mone and luteinizing hormone were assayed using a chemiluminescent
immunometric assay (Siemens Immulite 2000, Bayswater, VIC, Australia).
The participants were assessed with the Wechsler Test of Adult
Reading68 to obtain an estimate of premorbid intellectual functioning,
and a four subtest version of the Wechsler Adult Intelligence scale, third
edition69 comprising the Arithmetic, Digit Symbol, Similarities and Picture
Completion subtests to assess current intellectual functioning. The study
procedures were approved by the University of New South Wales and the
South Eastern Sydney and Illawarra Area Health Service Ethic Committees.
All the participants provided written informed consent before participation
in the study.
Study design
In a 13-week, randomized, double-blind, placebo-controlled, crossover trial
patients received 120 mg per day of encapsulated raloxifene and placebo
(encapsulated lactose) as an adjunctive treatment to their currently
prescribed antipsychotic medication (see Supplementary Figure 1). All
quality assessment/control testing of encapsulated raloxifene was
performed by IDT Australia (Boronia, VIC, Australia). Following a baseline
assessment, the participants were randomly assigned to receive raloxifene
(10 patients) or placebo (10 patients) for 6 weeks using a computer-
generated randomization schedule provided by the Prince of Wales
Hospital Pharmacy Clinical Trials Unit. Following the ﬁrst 6-week period of
the trial, there was a 1 week ‘washout’ period followed by the second 6-
week period when patients received the alternate treatment (raloxifene or
placebo). The patients were monitored throughout the trial to assess
potential adverse events and the compliance was determined by returned
pill counts and hormonal blood assays. The fMRI was used to measure
blood oxygen level-dependent (BOLD) signal changes as the patients
performed a facial emotion recognition task at week 6 (end of trial period
1) and at week 13 (end of trial period 2).
Facial emotion recognition task
During each test session, the participants completed a facial emotion
recognition task in the scanning environment (see Supplementary
Figure 2). The stimuli consisted of 60 unique color pictures of human
faces representing equal numbers of the following emotions: anger, fear,
happy, sad and neutral.46 Each of the ﬁve emotional expressions was
presented a total of 12 times. The stimuli were presented on an inverted
computer screen via a set of mirrors in the scanner for 5.5 s each and for
each presentation, the individuals were asked to identify the affect
displayed using a button response box.
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Table 1. Demographics, clinical characteristics and blood analyses of patients (n= 20)
Variable Baseline Placebo treatment Raloxifene treatment df t/Z value P
Age (years) 36.5 (8.5)
Education (years) 13.4 (2.1)
WAIS-III FSIQ
Estimated full-scale IQ 92.4 (10.0)
WTAR
Estimated premorbid IQ 104.0 (6.5)
Sex (M/F) 12/8
Race (total)
Caucasian 15
Asian 1
Caucasian/Asian 3
Other 1
Handedness (right/left) 19/1
Diagnosis
Schizophrenia 14
Schizoaffective 6
Age of onset 23.7 (6.3)
Illness duration 12.9 (6.8)
Number of hospitalizations
0–5 13
45 7
Antipsychotic dose (CPZ equivalent) 703.0 (590.0) 699.0 (592.0) 680.7 (574.7) 19 1.34 0.18
% On prolactin-raising antipsychotics 55%
Hormone assays
Prolactin (mIU ml− 1) 619.8 (654.6) 500.3 (457.7) 484.2 (474.4) 19 1.45 0.15
Luteinizing hormone 5.2 (5.0) 6.6 (6.8) 5.1 (4.6) 19 o0.001 1.0
Follicle stimulating hormone 9.2 (23.3) 9.1 (22.9) 9.8 (20.2) 19 2.07 0.04
PANSS
Positive 14.5 (4.9) 14.4 (5.7) 13.4 (4.4) 19 2.03 0.06
Negative 14.8 (6.4) 14.5 (4.7) 14.1 (5.7) 19 0.54 0.6
General 30.7 (7.9) 28.4 (6.6) 28.5 (6.9) 19 0.14 0.89
Total 60.0 (16.6) 57.3 (13.9) 56.0 (13.8) 19 0.76 0.46
Second-generation antipsychotics
Olanzapine 4
Clozapine 1
Amisulpride 2
Risperidone 2
Aripiprazole 1
Ziprasidone 1
Quetiapine 1
Clozapine+paliperidone 1
Clozapine+amisulpride 2
Clozapine+aripiprazole 1
Clozapine+chlorpromazine 1
Risperidone+quetiapine fumerate 1
Second- and ﬁrst-generation antipsychotics
Clozapine+haloperidol 1
Zuclopenthixol+olanzipine 1
Abbreviations: CPZ, chlorpromazine; PANSS, Positive and Negative Syndrome Scale; WAIS-III FSIQ, Wechsler Adult Intelligence Scale third edition Full-Scale
Intelligence Quotient; WTAR, Wechsler Test of Adult Reading. Prolactin-raising antipsychotics: amisulpride, chlorpromazine, haloperidol, ﬂupentixol,
paliperidone, risperidone, zuclopenthixol. Prolactin-sparing antipsychotics: aripiprazole, asenapine, clozapine, quetiapine fumerate, olanzapine, ziprasidone.
Total number of participants receiving any prolactin-raising medication is 11. The other nine participants were receiving one or a combination of
prolactin-sparing antipsychotics. Standard deviation in parentheses.
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Demographic and task statistical analyses
The data analysis was performed using IBM SPSS 22 for Windows (Armonk,
NY, USA). Antipsychotic dose, hormone levels, PANSS scores and task
performance measures were compared between treatment conditions
using t-tests or Wilcoxon rank-sum tests as appropriate. Task performance
included measures of accuracy (% correct responses) and reaction times
for each facial expression. Owing to technical problems, the behavioral
data were limited to 17 patients during the active raloxifene phase and 11
patients during the placebo phase.
Image acquisition and processing
Echoplanar MR brain images were acquired using a 3-Tesla Phillips Achieva
MRI scanner with an eight-channel bird-cage-type head coil at the
Neuroscience Research Australia, Randwick, NSW, Australia. Each partici-
pant received a T1-weighted high-resolution anatomical scan to screen for
structural abnormalities and for co-registration (TR (repetition time):
5.4 ms; TE (echo time): 2.4 ms; ﬁeld of view: 256 mm; matrix: 256 × 256;
sagittal plane; slice thickness: 1 mm, no gap; 180 slices). During the facial
emotion recognition task, 210 T2*-weighted MR images providing BOLD
contrast (TR/TE= 3000/30; 21 interleaved slices, slice thickness = 3.0 mm,
gap= 1.0 mm, voxel size = 3 × 3× 3 mm; ﬂip angle = 90°; ﬁeld of
view=24 cm) were acquired. Three dummy scans were obtained before
each fMRI data acquisition to allow for the equilibration of the MRI signal.
The BOLD fMRI data were preprocessed and analyzed using Statistical
Parametric Mapping software (SPM8; http://www.ﬁl.ion.ucl.ac.uk/spm)
running under MATLAB version 2012b. For each participant, the 210
volume functional time series images were realigned to the ﬁrst image in
the sequence and coregistered to the T1 anatomical scan. The images
were transformed into stereotactic space (Montreal Neurological Institute)
and smoothed with a 10 mm full-width half maximum Gaussian ﬁlter. All
data sets were screened for artefacts, excessive movement exceeding
3 mm translation on x, y or z axes and successful normalization. The
motion parameters were included as regressors in the ﬁrst-level analysis to
further control for motion effects.
fMRI analyses
At the ﬁrst level of analysis, a contrast was created for subject-level time
series to assess the difference in BOLD signal between conditions of
interest: angry faces versus neutral faces. At the second level, we ﬁrst
constructed single-sample t-test models for the active and placebo
conditions separately at the whole-brain level to assess the main task
effect for the recognition of angry faces. Next, to assess activation
differences between raloxifene and placebo conditions in speciﬁc regions
selected a priori, which have been previously shown to have a lower level
of activation during emotional face recognition in schizophrenia,46–48 we
performed paired t-tests between raloxifene and placebo conditions in the
regions of interest (ROIs). The following bilateral structural ROIs were
selected from the Anatomical Automatic Labelling Atlas in the SPM8
toolbox:70 amygdala, hippocampus and IFG. We corrected for multiple
comparisons across the whole-brain one-sample t-tests using false
discovery rate (FDR) corrections (Po0.05). Small volume corrections were
applied for ROIs (family-wise error, Po0.05).
RESULTS
Demographics, symptom measures, compliance and blood
analyses
Demographic and clinical characteristics of the study sample are
presented in Table 1. The men and women with schizophrenia in
this sample were chronically ill, treated primarily with second-
generation antipsychotics, and displayed mild-to-moderate symp-
tom severity based on PANSS scores. On the basis of returned pill
counts, compliance for period 1 of the trial was 97.6% and 97.3%
Figure 1. Coronal slices depicting areas of signiﬁcant neural activation during angry facial recognition in the (a) raloxifene and (b) placebo
conditions.
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for period 2 for this fMRI study. There were no severe adverse
events that were attributed to the study medication. There was no
statistically signiﬁcant difference between PANSS-positive and
-negative symptoms scores during raloxifene and placebo
conditions; however, there was a trend towards a statistically
signiﬁcant decrease in PANSS-positive symptom-severity scores
with raloxifene treatment. There were no clinically relevant
differences on the hormone panel measures between the
raloxifene and placebo conditions although there was a statisti-
cally signiﬁcant increase in follicle-stimulating hormone levels
with raloxifene treatment.
Behavioral results
The performance measures of participants on the facial emotion
recognition task included reaction times and response accuracy
(% correct) presented in Supplementary Table 1. The Wilcoxon
signed-rank tests indicated that there was no signiﬁcant difference
in accuracy and reaction time between adjunctive raloxifene and
placebo conditions.
Imaging
Whole-brain one-sample t-tests for angry versus neutral face
recognition revealed signiﬁcant activation for the raloxifene and
placebo conditions (see Figure 1, Table 2). During raloxifene
treatment, angry face recognition elicited bilateral activation in a
widespread network including inferior, middle, medial and super-
ior frontal gyrus, middle temporal gyrus, inferior parietal lobe,
insula, lingual gyrus, fusiform gyrus, parahippocampal gyrus and
cingulate gyrus (FDR, Po0.05). The placebo condition elicited
activation in a similar, yet more restricted network including
inferior, middle, medial and superior frontal gyrus and precentral
gyrus (FDR, Po0.05).
When comparing the three brain regions selected a priori by
ROI (amygdala, hippocampus and IFG bilaterally), the patients
showed greater activation only within the bilateral inferior frontal
gyrus and hippocampus with raloxifene treatment relative to the
placebo condition; however, only the left inferior frontal gyrus and
right hippocampus reached the strict statistical signiﬁcance level
(see Figure 2, Table 3). The placebo condition did not elicit greater
activation than the raloxifene treatment in any region during
recognition of angry faces. There were no signiﬁcant activation
differences between raloxifene and placebo conditions in relation
to the amygdala ROI.
DISCUSSION
The main aim of the present study was to determine the extent to
which raloxifene would inﬂuence neural activity associated with
recognition of faces with a negative valence in men and women
with schizophrenia. In accordance with our hypothesis, angry face
recognition elicited signiﬁcantly greater activation in the left IFG
and right hippocampus during raloxifene treatment relative to
placebo of the same individuals with schizophrenia studied over
time. However, we did not detect any change in performance
accuracy over the course of the study with raloxifene administra-
tion during facial emotion recognition in people with
schizophrenia.
The hippocampus is involved in emotion processing and has
been shown to be hypoactive in schizophrenia during facial
emotion processing tasks. Using the same emotion-recognition
paradigm as in the present study, Gur et al.46 found that people
with schizophrenia showed signiﬁcantly less activation in the
bilateral hippocampus relative to healthy controls during exposure
to positive and negative facial expressions. Although we did not
ﬁnd signiﬁcant increases in hippocampal activity in both the
hemispheres, we were able to detect an increase in activity of the
right hippocampus. Our ﬁnding of increased activation in ROIs
that are hemisphere-speciﬁc supports previous work showing
evidence for the laterization of emotion processing.71 Papanico-
laou et al.72 demonstrated specialization of the hippocampus in
healthy individuals where the left hippocampus activates during
mnemonic processing of verbal items and the right side activates
for processing visual stimuli that are difﬁcult to encode verbally.
Table 2. Whole-brain analysis showing regions of activation during anger processing in people with schizophrenia during raloxifene treatment and
placebo condition
Brain region Brodmann area L/R CS Peak coordinate T
x y z
Raloxifene treatment: main effect
Lingual gyrus (extends to middle occipital and inferior occipital gyrus) 18 R 1321 10 − 86 − 10 6.30
Lingual gyrus (extends to fusiform gyrus, cerebellum and parahippocampal gyrus) 18 L 1110 − 18 − 88 − 8 6.29
Fusiform gyrus 37 R 166 50 − 50 − 10 4.46
Inferior frontal gyrus (extends to middle frontal gyrus and insula) 44 L 2900 − 44 24 24 7.66
Inferior frontal gyrus (extends to insula) 47 R 119 30 34 6 4.82
Middle temporal gyrus 19 R 48 36 − 82 16 4.31
Middle occipital gyrus 19 L 104 − 32 − 84 16 6.33
Middle frontal gyrus 46 R 373 50 28 24 4.65
Inferior parietal lobe 7 L 242 − 32 − 48 44 5.37
Medial frontal gyrus (extends to medial and superior frontal gyrus, limbic lobe and
cingulate gyrus)
8 L 475 − 8 16 50 5.99
Placebo: main effect
Middle frontal gyrus (extends to inferior frontal gyrus) 46 L 535 − 48 28 24 6.77
Middle frontal gyrus (extends to inferior frontal gyrus) 9 R 81 42 12 32 4.68
Middle frontal gyrus 6 L 32 − 50 8 46 4.59
Precentral gyrus 6 L 42 − 42 − 4 44 5.47
Medial frontal gyrus (extends to superior frontal gyrus) 6 R 222 4 14 52 5.66
Abbreviations: CS, cluster size (voxels); L, left hemisphere; R, right hemisphere; T, t-value. Data are Montreal Neurological Institute coordinates for activation
signiﬁcant at false discovery rate, Po0.05.
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Similarly, Bellace et al.57 reported greater activation in the left
hippocampus for emotional words and the right hippocampus for
emotional pictures. Another fMRI study reported that encoding
faces was associated primarily with activation in the right
hippocampus.73 Thus, our ﬁnding of signiﬁcantly greater activa-
tion in the right hippocampus during raloxifene compared with
placebo may reﬂect the ability of raloxifene to enhance neural
processing of emotional visuospatial stimuli.
Several fMRI studies of emotion processing in schizophrenia
have found abnormal activity in cortical regions, particularly the
IFG. We previously reported hypoactivation of the left IFG in
people with schizophrenia relative to healthy controls during
angry face processing where matching the emotional face to the
correct emotional word is required.47 Similarly, Russell et al.74
showed less BOLD signal in the left IFG during a socioemotional
task in men with schizophrenia compared with healthy controls.
Furthermore, decreased functional connectivity of the IFG, which
may contribute to abnormalities during emotion processing, has
been reported during semantic processing61 and cognitive
processing.75 Goekoop et al.37 reported increased activation in
the left IFG following raloxifene treatment compared with placebo
in healthy elderly males during a face recognition task. Our ﬁnding
of increased activation in the left IFG with adjunctive raloxifene
supports ﬁndings of Goekoop et al.37 on the effect of raloxifene on
brain activity. Further, the left IFG includes Broca’s area which has
a role in verbal processing.76 The paradigm in the present study
requires subjects to match the facial emotion with the written
emotion displayed, thus marked increase in activation in the left
IFG during raloxifene may reﬂect increased verbal processing to
identify the presented visuospatial stimuli.
We did not observe any signiﬁcant changes in brain activation
in the amygdala during recognition of angry faces between
raloxifene and placebo conditions. Some neuroimaging studies
report hypoactivation of the amygdala during processing of facial
emotions, while others report normal or enhanced activation of
this region in people with schizophrenia.52–55 One study sought to
determine whether variability in amygdala activation may be
related to the time course of the experiment. People with
schizophrenia initially showed hyper-responsivity of the amygdala
to facial expressions relative to healthy controls; whereas in the
latter phase of the experiment, patients exhibited decreased
bilateral amygdala response.77 It has been well established that
amygdala response to facial expressions habituates with repeated
presentations;78,79 however, Suslow et al.77 demonstrated a more
rapid decrease in amygdala response over time in schizophrenia
relative to healthy people. Therefore, heterogeneous ﬁndings
regarding amygdala activation during emotional face processing
may result from differences in length of the experimental
paradigms, such that longer tasks are associated with habituation
of amygdala activity and therefore less activation when averaged
across time. Our study did not show a signiﬁcant difference in the
level of amygdala activation during placebo and raloxifene
conditions in schizophrenia. It is possible that raloxifene does
not affect activation in this region or that any increase in
activation was limited to the initial stimuli presentations and thus,
was not signiﬁcant when we averaged across the whole task.
The exact mechanism by which raloxifene exerts its effects is
not entirely known, but may involve neurotransmitter systems or
other neuromodulators. The action of raloxifene on mood may be
related to mimicking estrogenic effects on pre- and postsynaptic
modulation of serotonergic and/or dopaminergic neurotrans-
mission.80–82 A large body of evidence has shown that dopamine
neurotransmission inﬂuences hippocampal plasticity and
function,83–85 and there is an increase in dopaminergic activity
in the left inferior frontal gyrus during human emotion
processing.86 Raloxifene has also been shown to decrease the
Figure 2. Patients showed signiﬁcantly greater activation within the left inferior frontal gyrus and right hippocampus (small volume family-
wise error corrected, Po0.05.) during raloxifene treatment relative to the placebo condition.
Table 3. Region of interest analyses showing signiﬁcant treatment effects
Contrast L/R CS x y z T Z Brain region
Raloxifene 4 placebo L 86 − 44 − 48 4 5.80a 4.35 Inferior frontal gyrus
R 36 34 − 14 −24 4.71a 3.79 Hippocampus
Placebo 4 raloxifene None
Abbreviations: CS, cluster size; L, left hemisphere; R, right hemisphere; T, t-value; Z, z-value. aSmall volume family-wise error corrected, Po0.05. Signiﬁcant
activation differences in the hippocampus and inferior frontal gyrus following raloxifene treatment compared with placebo. Centers of activation clusters are
given by Montreal Neurological Institute stereotactic coordinates (x, y, z).
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inﬂammatory response in mouse and rat microglia cells in vitro.87
Our group recently found increased inﬂammatory mRNA expres-
sion in a subgroup of people diagnosed with schizophrenia
(approximately 40%) suggesting that anti-inﬂammatory therapies
may be of beneﬁt.88,89 Thus, it is possible that the ability of
raloxifene to reverse abnormalities in brain activation in patients
may, in part, be due to its ability to suppress inﬂammation.
Further, a number of studies have shown that raloxifene has
antioxidant properties;90,91 therefore, its beneﬁcial effects in
schizophrenia may be related to the control of oxidative stress,
which has been shown to be elevated in people with
schizophrenia.92
The hippocampus is one of the primary sites of estrogen
receptors in the brain; and in animal studies, estrogen adminis-
tration has been linked to increases in synaptic spine density.93
Raloxifene has also been shown to reduce neuronal loss in the
hippocampus.94 Our group previously demonstrated increased
activation of the right hippocampus during probabilistic associa-
tion learning with adjunctive raloxifene.41 Thus, our present
ﬁnding of increased neural activation in the hippocampus during
raloxifene administration is consistent with these previous
ﬁndings of the role of estrogen receptor modulation in the
hippocampus. We also ﬁnd increased activity in the prefrontal
cortex of people with schizophrenia, a brain region also
expressing estrogen receptors.95,96 Thus, the neural substrate of
SERM action may include direct effects in both the hippocampus
and IFG.
There are a number of limitations to our study. The limited
sample size did not allow us to evaluate sex differences. It is
possible that raloxifene affects neural activation related to
emotion processing differentially in male and female patients. In
addition, while the crossover design has the strength of
comparing the same person in different conditions, the use of a
crossover design can also be a limitation due to the potential for
any effects of treatment in the ﬁrst period carrying over into the
second placebo period for those who received raloxifene ﬁrst. In
that instance, we would be less likely to detect changes associated
with raloxifene; however, the carryover effect did not appear to
negatively inﬂuence our results given the effects of raloxifene on
brain activity reported. Although raloxifene has a relatively short
half-life, raloxifene may have prolonged effects on the brain cells;
therefore, future studies should use a parallel group design to
assess possible long-lasting effects. In addition, our sample was
not large enough to separate out individuals taking different
antipsychotic medications; a larger study would allow determina-
tion of whether raloxifene may have different effects in the
presence of particular antipsychotics. Our sample consisted of
patients displaying mild-to-moderate symptom severity on the
positive and negative syndrome scale, and it is possible that
raloxifene may have a more beneﬁcial effect on symptoms in
patients with more severe symptomatology. Last, we were unable
to obtain some task behavioral data for several participants due to
technical problems, which may have impacted our ability to
detect whether raloxifene had a statistically signiﬁcant effect on
emotional face recognition accuracy. However, others97–100 have
demonstrated that BOLD activity can be a more sensitive measure
of change than measures of behavior and can predict behavioral
decline. These studies illustrate the ability of fMRI to reveal
signiﬁcant neurobiological effects between groups in the absence
of behavioral differences, which may explain our ﬁndings of
activation differences in the ROIs while performance measures did
not vary.
Notwithstanding the limitations, we believe our study provides
the ﬁrst evidence of signiﬁcant effects of raloxifene treatment on
neural activation during a key component of social processing.
Owing to the clinical importance of social impairment in
schizophrenia and its relationship to poor functional outcomes,
the development of new treatments to improve this core deﬁcit is
one of the most pressing challenges in the ﬁeld. Our ﬁndings of
increased activity in the hippocampus and IFG during the
recognition of emotional faces with raloxifene suggest that
adjunctive raloxifene treatment facilitates hippocampal and IFG
activity in men and women with schizophrenia. These ﬁndings
indicate that future research on the use of raloxifene to treat social
impairment in schizophrenia is warranted. Given the emerging
evidence regarding the efﬁcacy of psychosocial treatments such
as cognitive behavioral therapy
and social skills training for improving social functioning in
schizophrenia,101,102 optimal outcomes may arise from a combina-
tion of pharmacologic therapy such as raloxifene with behavioral
interventions.
In conclusion, our double-blind, randomized, placebo-con-
trolled, crossover trial found that raloxifene treatment at 120 mg
per day enhanced brain activation in key regions involved in facial
emotion recognition deﬁcits in schizophrenia and thus, there is
potential for using adjunctive raloxifene treatment to reverse
social impairment in schizophrenia.
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